A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Way Crossover Study to Investigate the Effect of VALTREX 1g Once Daily for 60 Days on Viral Shedding in HSV-2 Seropositive Subjects With No Previous History of Symptomatic Genital Herpes Infection.
Phase of Trial: Phase IV
Latest Information Update: 24 Dec 2016
At a glance
- Drugs Valaciclovir (Primary)
- Indications Herpes genitalis; Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 12 Jun 2007 Status changed from in progress to completed.
- 14 Dec 2005 New trial record.